

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: IMAI13

In re Application of:	)	Conf. No.:
Yuji IMAI et al.	)	
	)	
IA No: PCT/JP03/00328	)	Art Unit:
	)	
IA Filed: January 17, 2003	)	Examiner:
	)	
Appln. No.: 10/501,675	)	Washington, D.C.
	)	
Filing Date: July 16, 2004	)	February 24, 2005
	)	
For: NOVEL PHOSPHOLIPASE A <sub>2</sub> AND	)	
GENE THEREOF	)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents  
 U.S. Patent and Trademark Office  
 Customer Service Window  
 Randolph Building, Mail Stop Amendment  
 401 Dulany Street  
 Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[ ] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

☒ B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114;

☒ 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

☐ A. Document(s) \_\_\_\_\_ is/are deemed substantially cumulative to document(s) \_\_\_\_\_, and, in accordance with 37 CFR §1.98(c), a copy of each of the former document(s) is not enclosed.

☐ B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

*(insert serial numbers and filing dates of prior applications)*  
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

☐ 3. Document(s) \_\_\_\_\_ is/are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

☐ An English translation of each document \_\_\_\_\_ (or of the pertinent portions thereof), or a copy of

an English-language abstract (or claim) is enclosed.

- ☐ For documents \_\_\_\_\_, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ is found in the attached \_\_\_\_\_ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ is set forth as follows:
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on page(s) \_\_\_\_\_ of the specification.
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on the attached sheet.

☒ 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

☒ 5. Other information being provided for the examiner's consideration follows:

International Search Report


6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is

(or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:



Sheridan Neimark  
Registration No. 20,520

SN:lmh  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

G:\BN\H\Hos\Imail13\PTO\ids.fee.doc



Rec'd PCT/PTO

24 FEB 2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

**Complete if Known**

Application Number	10/501,675
Filing Date	July 16, 2004
First Named Inventor	Yuji IMAI
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMAI13

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AE	Chiba H. et al., "Cloning of a Gene for a Novel Epithelium-specific Cytosolic Phospholipase A <sub>2</sub> , cPLA <sub>2</sub> δ, Induced in Psoriatic Skin", (March 26, 2004), The Journal of Biological Chemistry, Vol. 279, No. 13, pp. 12890-12897.	
	AF	Clark J. D. et al., "A Novel Arachidonic Acid-Selective Cytosolic PLA <sub>2</sub> Contains a Ca <sup>2+</sup> -Dependent Translocation Domain with Homology to PKC and GAP", (June 14, 1991), Cell, Vol. 65, pp. 1043-1051.	
	AG	Clark J.D. et al., GenBank Ac. No. M72393, sequence list.	
	AH	Pickard R.T. et al., "Molecular Cloning of Two New Human Paralogs of 85-kDa Cytosolic Phospholipase A <sub>2</sub> ", (March 26, 1999), The Journal of Biological Chemistry, Vol. 274, No. 13, pp. 8823-8831.	
	AI	Pickard R.T., GenBank Ac. No. AF065215, sequence list.	
	AJ	Song C. et al., "Molecular Characterization of Cytosolic Phospholipase A <sub>2</sub> -β", (June 11, 1999), The Journal of Biological Chemistry, Vol. 274, No. 24, pp. 17063-17067.	
	AK	Underwood K.W. et al., "A Novel Calcium-independent Phospholipase A <sub>2</sub> , cPLA <sub>2</sub> -γ, That Is Prenylated and Contains Homology to cPLA <sub>2</sub> ", (August 21, 1998), The Journal of Biological Chemistry, Vol. 273, No. 34, pp. 21926-21932.	
	AL	Underwood K.W. et al., GenBank AF058921, sequence list.	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.